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Background: The infusion of large amounts of Ringer’s lactate prolongs the functional gastrointestinal recovery
time and increases the number of complications after open abdominal surgery. We performed an open-labelled
clinical trial to determine whether hydroxyethyl starch or Ringer’s lactate exerts these adverse effects when the
surgery is performed by laparoscopy.
Methods: Eighty-eight patients scheduled for major abdominal cancer surgery (83% by laparoscopy) received a
first-line fluid treatment with 9 ml/kg of either 6% hydroxyethyl starch 130/0.4 (Voluven) or Ringer’s lactate, just after
induction of anaesthesia; this was followed by a second-line infusion with 12 ml/kg of either starch or Ringer’s
lactate over 1 hour. Further therapy was managed at the discretion of the attending anaesthetist. Outcome data
consisted of postoperative gastrointestinal recovery time, complications and length of hospital stay.
Results: The order of the infusions had no impact on the outcome. Both the administration of≥ 2 L of Ringer’s
lactate and the development of a surgical complication were associated with a longer time period of paralytic ileus
and food intolerance (two-way ANOVA, P < 0.02), but only surgical complications prolonged the length of hospital
stay (P < 0.001). The independent effect of Ringer’s lactate and complications of food intolerance time amounted to
2 days each. The infusion of≥ 1 L of hydroxyethyl starch did not adversely affect gastrointestinal recovery.
Conclusions: Ringer’s lactate, but not hydroxyethyl starch, prolonged the gastrointestinal recovery time in patients
undergoing laparoscopic cancer surgery. Surgical complications prolonged the hospital stay.Background
The choice between colloid and crystalloid fluid for
plasma volume support during surgery remains a con-
troversial issue. The current trend to use little (or no)
colloid fluid stems from studies in intensive care, where
the use of hydroxyethyl starch is associated with an in-
creased risk of acute kidney injury [1,2]. These findings
have not been replicated during general surgery [3,4],
where starch still has a role in goal-directed fluid ther-
apy, and for the treatment of hypovolaemia [5,6]. Rec-
ommendations from the European Medicines Agency
hold that the smallest amount possible of starch should
be used [7], which implies that the infused volumes of
crystalloid might increase.* Correspondence: r.hahn@telia.com
4Research Unit, Södertälje Hospital, and the Section for Anaesthesia,
Linköping University, Linköping, Sweden
Full list of author information is available at the end of the article
© 2015 Li et al.; licensee BioMed Central. This
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Colloids carry a risk of allergic reactions, but there are
also downsides with crystalloids that may complicate
and prolong postoperative care. Infusing more than 3 L
of crystalloid [8,9] or 12 ml/kg/hr [10] during open ab-
dominal surgery promotes complications such as pro-
longation of the gastrointestinal (GI) recovery time.
Infusion of about 6 L increases the risk of anastomotic
leakage, sepsis, pneumonia and wound infection [11],
while infusion of 7 L might be followed by fatal pulmon-
ary oedema [12]. Little is known about dose-dependent
adverse effects of colloids except for impairment of co-
agulation, which is mostly due to excessive dilution of
the plasma proteins. However, crystalloid fluid replaces
blood loss in the proportion of 3:1 and starch in the pro-
portion of 1:1, which means that larger fluid volumes
will be needed to maintain normovolaemia during sur-
geries if colloid fluids are banned.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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complications, with special reference to GI recovery, and
the length of hospital stay when the volumes and the
order of infusion of starch and Ringer’s lactate were var-
ied in a cohort of patients undergoing major abdominal
or pelvic surgery by the laparoscopic route. Since the
study of cholecystectomy by Holte et al. [13], crystalloid
programs have been more liberal in laparoscopic abdom-
inal surgery than in open surgery.
Methods
Patients
Between July 2011 and March 2013, 88 patients (American
Society of Anesthesiologists [ASA] class I or II) with sus-
pected or established gastric, colonic or rectal cancer were
recruited to participate in this open-labelled clinical trial.
The patients underwent laparoscopic or open GI surgery
under combined intravenous and inhalational general an-
aesthesia. Exclusion criteria were liver or renal dysfunction
(liver enzymes > 50% or serum creatinine > 50% of normal),
coagulation disturbances, obstructive pulmonary disease,
atrial fibrillation and mental disorders.
The protocol was approved by the Ethics Committee of
the First Affiliated Hospital, College of Medicine, Zhejiang
University (Hangzhou, PR of China; No. 2011150, Official
in charge: Zhangfei Shou) and registered at the Chinese
Clinical Trial Registry (http://www.chictr.org/en; No.
ChiCTR-TNRC-14004479). Written informed consent was
obtained from each study subject.
Procedure
Patients fasted overnight (no solid food or drink), and
no premedication was given. Anaesthesia was induced
at 8 AM with intravenous lidocaine, fentanyl and TCI-
guided propofol. Tracheal intubation was facilitated
with cisatracurium (0.2 mg/kg). The patients were
mechanically ventilated using a tidal volume of 8 ml/kg,
12 breaths/min and a positive end-expiratory pressure of
3 cm H2O. The anaesthesia was maintained with 1–2% of
sevoflurane, continuous infusion of propofol (target
plasma concentration, 2–3 μg/mL) and/or remifentanil
(0.10–0.20 μg/kg/min) and, if needed, intermittent doses
of cisatracurium.
Postoperative pain relief was managed by patient-
controlled intravenous analgesia (PCA) using sufentanil
100 μg in 100 ml in isotonic saline which was given at a
rate of 2 ml/h. Bolus injections were 2 ml using a lockout-
time of 5 min and a maximum of 30 ml during 4 hours.
Monitoring consisted of a bispectral index (BIS monitor)
where the anaesthesia was guided to reach a BIS value of
between 40 and 60. Central haemodynamics were followed
via the FloTrac™/Vigileo system and monitoring also in-
cluded pulse oximetry, electrocardiography and heart rate.
Urine was collected via a bladder catheter inserted justafter the tracheal intubation. Body temperature was main-
tained at 35.5°C or higher. Haemodynamic data from the
bolus infusions have been published elsewhere [14].
Measurements of blood haemoglobin and the serum
concentrations of creatinine, protein, albumin, glutamic
pyruvic transaminase and blood urea nitrogen were taken
before the surgery and on the first postoperative day.
Fluid therapy
No fluid was infused during the induction of general an-
aesthesia. Each patient was allocated to one of four fluid
programs consisting of a first-line bolus infusion initiated
about 10 min after tracheal intubation, and a second-line
continuous infusion initiated when surgery started.
GROUP 1. Bolus with starch, continuous with starch.
GROUP 2. Preloading with Ringer’s lactate, bolus with
starch, continuous with Ringer’s lactate.
GROUP 3. Bolus with starch, continuous with Ringer’s
lactate.
GROUP 4. Bolus with Ringer’s, continuous with Ringer’s
lactate.
The patients were not allocated to the four fluid pro-
grams individually but allocated in blocks of 25–30. They
reflect the beliefs, based on previous work, that the order of
the infusion may affect fluid retention and consequently
outcome [15] and that preoperative dehydration can in-
crease the number of postoperative complications [16].
Bolus infusions
Three bolus infusions of either 6% hydroxyethyl starch
130/0.4 (Voluven®; Fresenius Kabi Deutschland GmbH,
Bad Homburg, Germany) or Ringer's lactate. Each of the
boluses were given in the volume of 3 ml/kg over 7 min
via an infusion pump (IEC 601–1; Abbott Laboratories,
Chicago, IL).
Continuous infusions
When surgery was about to begin, a continuous infusion
of either starch or Ringer’s lactate was given via an infu-
sion pump at a rate of 12 ml/kg over 1 hour.
Further fluid therapy was given at the discretion of the
attending anaesthetist, but the volumes were recorded.
To prevent preoperative dehydration, 30 patients in the
starch + Ringer group (GROUP 2) also received preloading
with 500 mL of Ringer's lactate as a slow drip over 2 h, be-
ginning 3 h before the induction of anaesthesia.
Outcome measures
The outcome measures included the time period spent in
the postoperative care unit (PACU), time period of para-
lytic ileus, time to tolerance of oral food, length of hospital
stay and postoperative complications. The complications
were taken from the medical records from the in-hospital
period and interpreted according to the definitions used in
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Study (ISOS, see http://isos.org.uk). We considered post-
operative complications to include anastomotic leak, sur-
gical site infection, pneumonia, acute respiratory distress
syndrome, pulmonary oedema, sepsis, myocardial infarc-
tion, cardiac arrhythmias, cardiac arrest, vomiting, severe
pain, pulmonary embolism, stroke, postoperative haemor-
rhage, acute kidney injury and re-operation.
Statistics
The study was originally powered to differentiate be-
tween haemodynamic responses to the post-induction
bolus infusion [14]. A post hoc analysis showed that the
key outcome measure used in the present report, i.e. the
difference in food intolerance time between patients
who received < 2 L and ≥ 2 L of Ringer’s lactate, was de-
termined at the level of P < 0.05 with a power of 99.9%.
Data are presented as means (SD). Differences be-
tween groups were evaluated statistically by a one-, two-
or three-way analysis of variance (ANOVA).
Receiver operator characteristic (ROC) curves were
used to illustrate the fluid volume needed to predict pro-
longation of the postoperative period of food intolerance
to ≥ 5 days as well as the occurrence of any other com-
plication (IBM SPSS Statistics Version 22).
Significance was defined as P < 0.05.
Results
Treatment groups
The demographic data and surgical details were similar
in the four groups (Table 1, top). Eighty-three per cent
of the operations were performed by laparoscopy. No
patient was admitted to the ICU after the surgery.
Table 1 illustrates that the order of the infusions did
not affect the outcome parameters. However, the pa-
tients who received Ringer’s lactate, both for the bolus
and for the continuous infusion (Group 4), had a longer
PACU time and a longer period of time with food in-
tolerance, while the number of postoperative complica-
tions and the length of hospital stay were not increased
(Table 1, bottom).
The 22 patients who had a postoperative complication
stayed longer in hospital and were also slightly older
than the others (Table 2).Univariate analyses
A comparison was made between the outcomes of all
patients who received < 2 L or ≥ 2 L of Ringer’s lactate,
regardless of study group. Those given ≥ 2 L had a longer
PACU time and a longer period of time with paralytic
ileus and food intolerance, while postoperative complica-
tions and the length of hospital stay were not increased
(Table 3).The 66 patients who received ≥ 1 L of starch had
shorter PACU time (65 versus 96 min; P < 0.001) and a
shorter time of food intolerance (4.6 versus 6.5 days, P <
0.002). A smaller fraction of these patients developed
one or several postoperative complications (13.6% versus
28.8%), but this difference did not reach statistical sig-
nificance (P = 0.14).
Multivariate analyses
A two-way ANOVA confirmed that both Ringer’s lac-
tate ≥ 2 L and complications prolonged the period of
paralytic ileus and food intolerance, while only complica-
tions prolonged the length of hospital stay (Table 4).
For example, no complications and Ringer’s lactate < 2 L
had a mean period of paralytic ileus of 2.9 (1.1) days, and ≥
2 L was associated with 3.5 (0.9) days. The corresponding
time periods for patients with complications were 3.6 (1.3)
and 4.4 (1.3) days, respectively (Figure 1A). The effect of
Ringer’s lactate and complications on the food intolerance
time was somewhat greater, amounting to about 2 days
each (Figure 1B). No independent effect on PACU time
was found.
In contrast, the infusion of ≥ 1 L of starch reduced the
time period of food intolerance by 2 days (P < 0.005)
when simultaneously considering the effect of surgical
complications (P < 0.014; two-way ANOVA).
When testing all three factors simultaneously, only
Ringer’s lactate ≥ 2 L and complications prolonged the
period of food intolerance (both P < 0.02), while the alle-
viating effect of ≥ 1 L of starch did not reach statistical
significance (P = 0.17).
ROC curves
The most appropriate cut-off for the fluid volume that
affected the postoperative food intolerance time to ≥
5 days amounted to ≥ 1.75 L for Ringer’s lactate and ≥
1 L for starch (Figure 2A). The area under the ROC
curves was 0.71 (Ringer’s lactate) and 0.34 (starch, both
P < 0.05).
Figure 2B illustrates the sensitivity and specificity of
perioperative parameters to indicate the occurrence of a
surgical complication. The area under the ROC curves
was 0.76 (hospital time), 0.70 (food intolerance time)
and 0.67 (paralytic ileus, all P < 0.05) while the fluids had
0.57 (Ringer’s lactate) and 0.56 (starch, none being statis-
tically significant).
Exploratory analyses
No statistically significant difference in total urine output
was found among the four groups (Table 1). However, the
excreted urine divided by the sum of infused starch and
Ringer’s lactate was lower in ‘Ringer’s-lactate-only’ Group
4 compared with the pooled data from the three starch
groups (20% [SD 11] versus 13% [6], P < 0.02).
Table 1 Details of patients, surgeries and fluid treatment, selected blood parameters and outcome measures
Fluid treatment Group 1 Group 2 Group 3 Group 4
ANOVA
Preloading 500 ml No Yes No No
Bolus infusion 9 ml/kg Starch Starch Starch Ringer
Continuous infusion 12 ml/kg/1 hr Starch Ringer Ringer Ringer
N 20 28 18 22
Age (years) 62 (10) 58 (13) 56 (12) 63 (8) NS
Body weight (kg) 59 (7) 59 (8) 62 (8) 58 (8) NS
Males (per cent) 75 54 72 77
Gastric/colonic/rectal cancer (N) 11/2/7 5/9/14 0/7/11 17/3/2
Open surgery (N) 5 4 5 1
Anaesthesia time (min) 262 (96) 272 (62) 269 (60) 242 (65) NS
Operating time (min) 206 (97) 201 (64) 206 (63) 195 (62) NS
Blood loss (ml) 205 (138) 160 (114) 200 (89) 194 (114) NS
Urine output (ml) 516 (402) 557 (168) 441 (286) 361 (156) NS
Starch (ml) 1125 (235) 1018 (94) 1000 (0) 420 (179) P < 0.001
Ringer’s lactate (ml) 1475 (472) 1438 (534) 1333 (542) 2295 (480) P < 0.001
Erythrocytes (N; ml) 5; 420 (277) 1; 700 1; 300 6; 454 (282)
Plasma (N; ml) 0 1; 500 1; 230 3; 417 (40)
Blood haemoglobin (g/L)
Before surgery 128 (17) 124 (24) 127 (24) 124 (22) NS
After surgery 112 (15) 115 (15) 113 (19) 111 (16) NS
Serum creatinine (μmol/L)
Before surgery 69 (13) 68 (17) 65 (14) 75 (14) NS
After surgery 63 (12) 61 (18) 58 (12) 64 (10) NS
Time in PACU (min) 71 (25) 60 (23) 66 (34) 97 (40) P < 0.001
Paralytic ileus (days) 3.2 (0.9) 3.6 (1.4) 2.7 (0.9) 3.5 (1.1) P = 0.054
Food intolerance (days) 4.5 (1.9) 4.6 (1.9) 4.6 (2.4) 6.5 (3.5) P < 0.03
Complications per operation 0.35 0.36 0.28 0.23 NS
Infectious complications (N) 5 2 3 1
Bleeding complications (N) 1 3 1 1
Length of hospital stay (days) 13.0 (4.6) 13.9 (2.6) 13.3 (3.0) 13.3 (4.7) NS
Data are the mean (SD) or the actual number (N) of patients. NS = not statistically significant.
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surgery had no statistical correlation with the outcome
measures, though there was a trend toward higher urine
flow in open surgery (urine flow 2.2 versus 1.7 ml/min).
Cardiac output was lower at the end of the bolus infu-
sions in the “Ringer’s-lactate-only” group (3.1 [SD 0.4] L/
min versus 3.6 [0.7] L/min, P < 0.003) but differences had
cancelled out at 1 hour of surgery. At that time, the car-
diac output for all patients was 4.7 (1.4) L/min, which rep-
resented 78% (SD 22) of baseline (i.e. before the induction
of anaesthesia). However, at 1 hour, the heart rate was
lower compared to baseline in those who had received a
combination of both starch and Ringer’s lactate (73% [SD
15] bpm) as compared to those who had received only
one of these fluids (87% [SD 17] bpm; P < 0.001; Table 5).Blood chemistry showed similar values before and after
the surgery. The mean decrease in the blood haemoglobin
concentration was 9%, total protein and bilirubin 10%, al-
bumin 13% and blood urea nitrogen decreased by 15%,
while the glutamic pyruvic transaminase increased by
39%. Serum creatinine decreased by 11% (Table 1) without
being statistically related to the amount of starch used.
Discussion
Infusion of ≥ 2 L of Ringer’s lactate prolonged food in-
tolerance time by 2 days, while infusion of ≥ 1 L of
hydroxyethyl starch did not have this effect. Beyond the
GI recovery, the fluid volumes used did not correlate
with the number of postoperative complications, such as
infection and bleeding. However, patients who developed
Table 2 Comparison of operations with and without
postoperative complications
No complications Complications ANOVA
N 66 22
Age (years) 58 (12) 64 (9) P < 0.05
Body weight (kg) 60 (9) 59 (6) NS
Males (per cent) 71 59
Anaesthesia
time (min)
250 (68) 295 (72) P < 0.01
Operating time (min) 190 (65) 235 (78) P < 0.01
Blood loss (ml) 175 (107) 229 (131)
Urine output (ml) 426 (225) 614 (359) P < 0.02
Starch (ml) 860 (328) 1000 (267) NS
Ringer’s lactate (ml) 1655 (681) 1590 (453) NS
Erythrocytes (N; ml) 6; 432 (264) 6; 466 (272)
Plasma (N; ml) 3; 335 (228) 2; 213 (205)
Time in PACU (min) 76 (35) 66 (27) NS
Paralytic ileus (days) 3.1 (1.1) 3.8 (1.3) P < 0.01
Food intolerance
(days)
4.6 (2.2) 6.2 (3.2) P < 0.03
Length of hospital
stay (days)
12.7 (3.4) 15.6 (3.9) P < 0.002
Data are the mean (SD) or the actual number (N) of patients. NS = not
statistically significant.








Age (years) 58 (12) 63 (10) P < 0.05
Body weight (kg) 60 (8) 59 (7) NS
Males (per cent) 67 70
Anaesthesia time (min) 258 (74) 268 (68) NS
Operating time (min) 196 (76) 211 (63) NS
Blood loss (ml) 167 (93) 221 (138) P < 0.05
Urine output (ml) 444 (258) 502 (286) NS
Starch (ml) 1009 (225) 705 (361) P < 0.001
Ringer’s lactate (ml) 1236 (358) 2310 (348) P < 0.001
Erythrocytes (N; ml) 4; 183 (416) 6; 416 (40)
Plasma (N; ml) 6; 367 (175) 7; 518 (308)
Time in PACU (min) 66 (30) 86 (37) P < 0.01
Paralytic ileus (days) 3.1 (1.2) 3.7 (1.1) P < 0.023
Food intolerance (days) 4.4 (2.1) 6.1 (3.0) P < 0.004
Complications per operation 0.27 0.21 NS
Infectious complications (N) 7 4
Bleeding complications (N) 3 3
Length of hospital stay (days) 13.3 (3.7) 13.7 (3.9) NS
Data are the mean (SD) or N = the number of patients. NS = not
statistically significant.
Table 4 Significance levels in two-way ANOVA evaluating
simultaneously the effect of administration of 2 L or more
of Ringer’s lactate and postoperative surgical complications
on various outcome measures in 88 patients
Ringer’s lactate ≥2 L Complications
Anaesthesia time (min) NS P < 0.03
Operating time (min) NS P < 0.03
Blood loss (ml) NS NS
Urine output (ml) NS P < 0.04
Time in PACU (min) P = 0.05 NS
Paralytic ileus (days) P < 0.02 P < 0.01
Food intolerance (days) P < 0.004 P < 0.007
Length of hospital
stay (days)
NS P < 0.001
NS = not statistically significant.
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and food intolerance that was clearly additive to the ef-
fect of ≥ 2 L of Ringer’s lactate.
We hoped to disclose differences in outcome depend-
ing on the sequence of infusing these fluids, but found
no such effects. Starch given as the first infusion after
induction of general anaesthesia yielded virtually identi-
cal outcome measures, regardless of whether starch was
continued or switched to Ringer’s lactate, or when dehy-
dration had been prevented by slowly infusing 500 ml of
Ringer’s lactate in the early morning before surgery
(Table 1).
Only when using Ringer’s lactate for both the first and
second fluid infusion was there a significant prolonga-
tion of the time required for overcoming the surgery-
induced paralytic ileus and food intolerance. However,
the prolongation actually became apparent in all patient
groups when the amount of infused Ringer’s lactate was
2 L. In fact, the ROC curve revealed a clear trend toward
a prolongation of the food intolerance time in response
to as little as ≥ 1.25 L of Ringer’s lactate (Figure 2A).
Hydroxyethyl starch maintained urinary excretion as
well as, or even better than, Ringer’s lactate during these
lengthy (mean 4 hrs) laparoscopic surgeries, which is
probably due to an improvement of the renal perfusion.
Our recordings of central haemodynamics provided no
good explanation for this finding. Changes in serumcreatinine levels were minimal and did not correlate with
the amount of infused starch, which has been an issue
[1-4]. Starch also seemed to reduce the duration of para-
lytic ileus (Figure 2A). However, the multivariate analysis
suggested that most of this effect could be explained by a
need for a smaller volume of Ringer’s lactate when a large
amount of starch was infused.
Figure 1 Duration of paralytic ileus (A) and food intolerance
(B) depending on infusion of either < 2 L or≥ 2 L of Ringer’s lactate
during surgery and whether postoperative complications developed.
(C) The length of hospital stay increased with the number of
complications (ANOVA P < 0.002). Data are the mean, and the error
bars are the standard deviation. The number of patients in each
group is indicated in red.
Figure 2 ROC curves illustrating the fluid volume needed (A) to
predict prolongation of the postoperative period of food intolerance
to≥ 5 days and (B) to predict the occurrence of any other
complication. Closeness to the reference line implies lack
of relationship.
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on outcome after open abdominal surgery has been
recognised for more than a decade [8-12,17,18]. A re-
strictive fluid policy facilitates wound healing and re-
duces the time required for GI recovery, and sometimes
reduces the length of hospital stay. “Zero balance” has
even been proposed [19,20]. However, not all of the previ-
ous authors found advantages in using a restrictive fluid
policy. MacKay et al. [21] replicated the pioneering workby Lobo [8] but did not report the same benefits, despite
the inclusion of three times as many patients. Kabon et al.
[22] could not find any difference in wound healing after
infusing very large fluid volumes (16–18 ml/kg/hr) com-
pared to smaller volumes (8 ml/kg/hr).
A meta-analysis by Varadhan & Lobo [9] showed that
fluid volumes between 1.75 and 2.75 L per day are asso-
ciated with better overall outcomes. This conclusion is
valid for crystalloid fluid during open abdominal surgery,
Table 5 Selected haemodynamic parameters measured with FloTrac/Vigileo
Fluid treatment Group 1 Group 2 Group 3 Group 4
ANOVA
Preloading 500 ml No Yes No No
Bolus infusion 9 ml/kg before surgery Starch Starch Starch Ringer
Continuous infusion 12 ml/kg/1 hr Starch Ringer Ringer Ringer
Cardiac output (L/min)
Before anaesthesia 5.8 (1.6) 6.1 (1.6) 7.1 (2.2) 6.2 (1.4) NS
Beginning of surgery 3.5 (0.7) 3.6 (0.6) 3.6 (0.7) 3.1 (0.4) P< 0.03
1 hour of surgery 5.0 (1.4) 4.5 (1.4) 4.8 (1.6) 4.6 (1.3) NS
Relative to before anaesthesia (%) s
After bolus infusions 63 (19) 61 (16) 55 (19) 53 (13) NS
1 hour of surgery 90 (24) 75 (18) 70 (23) 78 (20) P< 0.03
Mean arterial pressure (mmHg)
Before anaesthesia 101 (13) 106 (14) 107 (12) 109 (10) NS
Beginning of surgery 71 (10) 76 (91) 70 (8) 70 (11) NS
1 hour of surgery 92 (16) 95 (16) 97 (31) 93 (19) NS
Relative to before anaesthesia (%)
Beginning of surgery 70 (9) 72 (10) 66 (8) 65 (10) P< 0.03
1 hour of surgery 92 (16) 90 (16) 92 (31) 86 (19) NS
Heart rate (bpm)
Before anaesthesia 75 (11) 79 (14) 84 (18) 72 (9) NS
Beginning of surgery 59 (7) 56 (8) 56 (8) 55 (8) NS
1 hour of surgery 64 (9) 56 (10) 61 (11) 60 (9) P< 0.03
Relative to before anaesthesia (%)
Beginning of surgery 73 (10) 72 (15) 69 (12) 78 (8) NS
1 hour of surgery 88 (19) 73 (14) 74 (18) 86 (14) P< 0.002
Data are the mean (SD).
Li et al. BMC Anesthesiology  (2015) 15:72 Page 7 of 8but little is known about the effect of colloid and crystal-
loid fluid on the outcome after laparoscopic surgery.
The present study fills in this gap by showing that ≥ 2 L
of Ringer’s lactate significantly prolongs the GI recovery
time during laparoscopic cancer surgery, both in patients
with and without postoperative complications.
Many authors report slow GI recovery as a complica-
tion, which makes it difficult to separate the contribu-
tions of fluid-dependent and fluid-independent adverse
events to the length of hospital stay [17]. Here, GI re-
covery was considered separately from other outcome
parameters. By doing so, we disclosed clear relationships
between fluid volumes and GI recovery but no relation-
ship between fluid volumes and surgical complications
like bleeding and infection (Table 2, Figure 2B). How-
ever, when evaluating this result, one must consider that
excessive amounts of crystalloid or colloid fluid were
never used. The largest volume of Ringer’s lactate
amounted to 3 L and the largest volume of starch was
1.5 L. Although the volumes used are far from those as-
sociated with pulmonary problems [11,12], the benefits
of crystalloid fluid restriction can still be extended tolaparoscopic surgery, as only 17% of the present opera-
tions were performed by an open approach.
Limitations include the fact that the study was an open-
labelled trial in which all patients received both fluids. The
volumes differed, except for the post-induction bolus
rounds and the first hour of surgery when the fluid therapy
was strictly standardised. The study was originally powered
to differentiate between the haemodynamic responses to
the post-induction bolus infusions with starch and Ringer’s
lactate [14] although our post hoc power analysis showed
that valuable information could be obtained about outcome
measures as well. Complications were collected from the
medical records and not by a prospective survey. The un-
even number of patients in the Tables can be explained by
the lack of access to the postoperative charts for the first
studied 23 patients, who therefore had to be excluded. This
problem was due to a change of hospital by the author who
organised the data collection (Y.L.).
The incidence of postoperative nausea was low and mild
in form, and just like prolonged GI recovery, was not in-
cluded in the group of surgical complications. We regard
the other outcome measures to be trustworthy and valid.
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taken the first day after the surgery, while kidney injury
can be more clearly distinguished on the second and third
postoperative day. However, if the kidneys are harmed, an
increase is still apparent on the first postoperative day [2].
Conclusions
In 88 patients who underwent major abdominal or pelvic
surgery, usually via the laparoscopic route (83%), the use
of 6% hydroxyethyl starch 130/0.4 (Voluven) did not pro-
long the time period required for postoperative GI recov-
ery. In contrast, administration of ≥ 2 L of Ringer’s lactate
increased the duration of paralytic ileus by 0.7 days and of
food intolerance by 2 days, regardless of whether GI re-
covery was prolonged by surgical complications.
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